arrow
C

Christopher T. Ritchlin

university of rochester medical school
H指数:76
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Sonelokimab,一种抑制IL-17A/IL-17F的纳米抗体,用于活动性银屑病关节炎:一项随机、安慰剂对照的2期试验

2025-10-060
OAAI
Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study

通过 guselkumab 抑制活动性银屑病关节炎患者结构损伤进展:3b 期、随机、双盲、安慰剂对照 APEX 研究第 24 周结果

2025-10-010
PRE
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

研究总结:Bimekizumab在银屑病关节炎患者中的安全性与有效性:两项III期研究2年结果

2025-05-100
OA
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies (vol 11, pg 1363, 2024)

贝美克单抗在银屑病关节炎患者中的安全性与有效性:两项III期研究2年结果(卷11,页1363,2024)

2025-05-050
OAAI
Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling

Guselkumab结合CD64+ IL-23产生髓系细胞,增强了中和IL-23信号的能力

2025-03-121
OA
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Bimekizumab在银屑病关节炎患者中的安全性与有效性:两项III期研究的2年结果

2024-08-310
OAAI
RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OVER 2YEARS IN FUTURE 5

在FUTURE 5研究中,探讨经Secukinumab治疗2年的银屑病关节炎患者中,抑制放射学进展与实现低疾病活动度或缓解及其核心组成部分之间的关系。

2024-06-010
PRE